Dataset Information

Dissection of the T-cell infiltrate in mouse pancreatic tumors reveals an extensive and diverse tumor-reactive T-cell repertoire

ABSTRACT: Background: Pancreatic ductal adenocarcinoma (PDAC) is refractory to cytostatic and immunotherapeutic treatment regimens, including immune checkpoint inhibition (ICI). The latter is due to the limited mutational load of most of these tumors, in combination with the immunosuppressive hurdles imposed by the tumor microenvironment. Here we present an in-depth analysis of the T-cell response at the single-cell level in an orthotopic PDAC mouse model that recapitulates the therapy resistance of the human disease. In parallel, we investigated an ICI-sensitive variant of this model expressing an immunogenic neo-antigen. Methods: Single-cell RNA and T-cell receptor (TCR) from tumor-infiltrating lymphocytes (TILs) of 14 tumor-bearing mice were combined with functional in vitro screening of TCR specificity against tumor. Transcriptomic differences between tumor-reactive (TR) and non-tumor-reactive (NTR) T-cells were harnessed to define gene signatures for the purpose of predicting the specificity of additional TCRs. Results: Our efforts revealed extensive tumor-reactive and bystander CD8+ and CD4+ T-cell repertoires, not only in the immunogenic but also in the ICI-refractory tumors. By integrating the functional screening and single-cell transcriptome data sets, we delineated gene signatures that distinguish between tumor-reactive and bystander T-cells in the mouse model as well as in human cancers. The TCRs in the murine models detect a range of tumor-associated antigens beyond mutanome-encoded neoepitopes and retain functional anti-tumor activity in vitro.

ORGANISM(S): Mus musculus

PROVIDER: GSE217121 | GEO | 2025/06/01

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Background Clinical success of T cell receptor (TCR) gene therapy has previously been demonstrated for NY-ESO-1 TCR gene therapy. To increase numbers of cancer patients that can be treated with TCR gene therapy we aimed to identify a novel set of high-affinity cancer specific TCRs targeting different cancer testis (CT) antigens in prevalent HLA class I alleles. Methods In this study, we selected based on publicly available gene expression databases the most promising CT genes to target. From these selected genes we identified by HLA peptidomics the naturally processed and presented HLA class I peptides. With these peptide-HLA tetramers were generated, and by single cell sorting CT specific CD8+ T cells were selected, and expanded from the allo-HLA repertoire of healthy donors. By several functional assays high avidity CT-specific T cell clones with safe recognition pattern were selected. To evaluate the potential for clinical application in TCR gene therapy, TCRs were sequenced and transferred into peripheral blood derived CD8+ T cells. Results In total we identified, 7 novel CT-specific TCRs that effectively target MAGE-A1, MAGE-A3, MAGE-A6 and MAGE-A9 in the context of human leukocyte antigen(HLA) -A1, -A2, -A3, -B7, -B35 and -C7. TCR gene transfer into CD8⁺ T cells resulted in efficient cytokine production and cytotoxicity of variety of different tumor types without detectable cross-reactivity. In addition, major in vivo antitumor effects of MAGE-A1 specific TCR engineered CD8⁺ T cells was observed in an orthotopic xenograft model for established multiple myeloma, in which bone marrow located tumor cells were completely eradicated after T cell injection. Conclusion The identification of 7 novel CT-specific TCRs, reactive against CT antigens presented in a variety of different HLA class I alleles, allows selection of therapeutic TCRs for an increased number of cancer patients, and will improve development of personalized TCR gene therapy.

Dataset Information

Dissection of the T-cell infiltrate in mouse pancreatic tumors reveals an extensive and diverse tumor-reactive T-cell repertoire

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets